Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer Presented at 2025 American Association for Cancer Research (AACR) Annual Meeting
Study Administered CRISPR genetically engineered CISH-knockout Tumor Infiltrating Lymphocytes as a Model System to Evaluate the Safety and Efficacy of this Classically Undruggable Intracellular Target